Tags

Type your tag names separated by a space and hit enter

Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Thromb Haemost. 1996 Nov; 76(5):729-34.TH

Abstract

In the present study the effect of oral contraceptive (OC) treatment on selected factors involved in the activation, i.e. circulating activated factor VII (cFVIIa), and in the inhibition of blood coagulation, i.e. plasma protein S activity and circulating thrombomodulin (cTM), were for the first time measured in OC users in a prospective study. Beside other coagulation variables, these parameters were measured during treatment with three low estrogen formulations containing different gestagen components (norgestimate, gestodene). During OC treatment increases in the activation markers prothrombin fragment F1 + 2 and D-Dimer were found, suggesting an increased activation of blood coagulation and fibrinolysis. Along with elevated plasma levels of FVII antigen, cFVIIa was also found increased in all three treatment groups, while inhibitory components of blood coagulation, plasma protein S activity and cTM, significantly and similarly decreased during treatment in all three treatment groups. We conclude that low dose estrogen pills induce similar changes in the plasma levels of main regulatory components of blood coagulation, despite differences in their gestagen components. Increased levels of activators and decreased activities of inhibitors may contribute to arterial and venous thrombotic complications seen in predisposed OC users.

Authors+Show Affiliations

Clinical Institute of Medical and Chemical Laboratory Diagnostics, University of Vienna, Austria.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

8950781

Citation

Quehenberger, P, et al. "Increased Levels of Activated Factor VII and Decreased Plasma Protein S Activity and Circulating Thrombomodulin During Use of Oral Contraceptives." Thrombosis and Haemostasis, vol. 76, no. 5, 1996, pp. 729-34.
Quehenberger P, Loner U, Kapiotis S, et al. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost. 1996;76(5):729-34.
Quehenberger, P., Loner, U., Kapiotis, S., Handler, S., Schneider, B., Huber, J., & Speiser, W. (1996). Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thrombosis and Haemostasis, 76(5), 729-34.
Quehenberger P, et al. Increased Levels of Activated Factor VII and Decreased Plasma Protein S Activity and Circulating Thrombomodulin During Use of Oral Contraceptives. Thromb Haemost. 1996;76(5):729-34. PubMed PMID: 8950781.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. AU - Quehenberger,P, AU - Loner,U, AU - Kapiotis,S, AU - Handler,S, AU - Schneider,B, AU - Huber,J, AU - Speiser,W, PY - 1996/11/1/pubmed PY - 1996/11/1/medline PY - 1996/11/1/entrez KW - Austria KW - Biology KW - Blood Coagulation Effects KW - Clinical Research KW - Comparative Studies KW - Contraception KW - Contraceptive Agents KW - Contraceptive Agents, Estrogen KW - Contraceptive Agents, Female KW - Contraceptive Agents, Progestin KW - Contraceptive Methods KW - Developed Countries KW - Ethinyl Estradiol KW - Europe KW - Family Planning KW - Fibrinolysis KW - Gestodene KW - Hematological Effects KW - Hemic System KW - Norgestimate KW - Oral Contraceptives KW - Oral Contraceptives, Combined KW - Oral Contraceptives, Phasic KW - Physiology KW - Research Methodology KW - Studies KW - Western Europe SP - 729 EP - 34 JF - Thrombosis and haemostasis JO - Thromb Haemost VL - 76 IS - 5 N2 - In the present study the effect of oral contraceptive (OC) treatment on selected factors involved in the activation, i.e. circulating activated factor VII (cFVIIa), and in the inhibition of blood coagulation, i.e. plasma protein S activity and circulating thrombomodulin (cTM), were for the first time measured in OC users in a prospective study. Beside other coagulation variables, these parameters were measured during treatment with three low estrogen formulations containing different gestagen components (norgestimate, gestodene). During OC treatment increases in the activation markers prothrombin fragment F1 + 2 and D-Dimer were found, suggesting an increased activation of blood coagulation and fibrinolysis. Along with elevated plasma levels of FVII antigen, cFVIIa was also found increased in all three treatment groups, while inhibitory components of blood coagulation, plasma protein S activity and cTM, significantly and similarly decreased during treatment in all three treatment groups. We conclude that low dose estrogen pills induce similar changes in the plasma levels of main regulatory components of blood coagulation, despite differences in their gestagen components. Increased levels of activators and decreased activities of inhibitors may contribute to arterial and venous thrombotic complications seen in predisposed OC users. SN - 0340-6245 UR - https://www.unboundmedicine.com/medline/citation/8950781/Increased_levels_of_activated_factor_VII_and_decreased_plasma_protein_S_activity_and_circulating_thrombomodulin_during_use_of_oral_contraceptives_ L2 - https://www.lens.org/lens/search/patent/list?q=citation_id:8950781 DB - PRIME DP - Unbound Medicine ER -